Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
(Abstracted from J Clin Oncol 2024;42:3550–3560) The field of precision medicine attempts to treat conditions with combinations that are tailored to the individual and the disease; precision oncology uses techniques to identify molecular defects in tumors and treat them with targeted interventions. For both breast and ovarian cancers, previous literature has shown that homologous recombination deficiency (HRD) can be treated with poly(ADP-ribose) polymerase (PARP) inhibitors and platinum salts.
Authors
- Erik N. Bergstrom (ORCID: https://orcid.org/0000-0001-7740-022X)
- Ammal Abbasi (ORCID: https://orcid.org/0000-0003-0623-2243)
- Sylvain Ladoire (ORCID: https://orcid.org/0000-0002-0331-9194)
- Scott M. Lippman (ORCID: https://orcid.org/0000-0002-1643-4124)
- Ludmil B. Alexandrov (ORCID: https://orcid.org/0000-0003-3596-4515)
- Loïck Galland
- Marcos Díaz‐Gay (ORCID: https://orcid.org/0000-0003-0658-0467)
Publication Details
- Journal
- Obstetrical & Gynecological Survey
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1097/ogx.0000000000001380
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00